昌吉那家医院检查精子比较好(昌吉割包皮该怎么治疗) (今日更新中)

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

NANJING, April 23 (Xinhua) -- At a time when almost every commodity in China is getting more expensive, the dwindling cost of medicine is a rarity.Zhang Jinkui, a hypertension patient, buys medicines from the community health center of his neighborhood in Changzhou, a city in east China's coastal Jiangsu Province.His prescription list includes Aspirin Enteric-coated tablets, down to 1.4 yuan from 4.7 yuan (0.7 U.S. dollars) per unit, and Fosinopril Sodium Tablets, down to 41.39 yuan from 51.6 yuan per unit.Both drugs are found on the essential drug list unveiled in 2009. The list names the 307 most common western and traditional Chinese medicines, which are heavily subsidized so hospitals can sell them at cost price.A consumer buys medicines with the help of a retailer at a pharmacy in Lianyungang, east China's Jiangsu Province, March 28, 2011.All essential medicines are listed by their generic names, and drug producers compete to supply essential medicines through public procurement.Due to a long history of low government funding for state-run hospitals, which often covers only 10 percent of the hospitals' operating costs, doctors have generated income for hospitals by aggressively prescribing expensive, and sometimes unnecessary, medicines and treatments.The essential medicine system and the reform of publicly funded hospitals, two pillars of China's health reform, are designed to address high medical costs and low accessibility of medical services.In April 2009, China kicked off health reforms aimed at correcting these long-standing problems facing China's health system and easing public grievances.Two years later, the essential medicine system has reduced drug prices, but still fails to please hospitals, patients and drug producers.The system requires government-funded grassroots health clinics, including urban community health centers and rural clinics, to prescribe only essential medicines and to sell these medicines at cost price, rather than with the previous 15 percent mark-up.Such policies have brought hard times to grassroots health clinics, especially in cash-strapped areas.Song Wenzhi, a public health professor at Peking University, said "Grassroots health clinics, without the expertise to perform operations and other treatments, rely heavily on selling drug," adding that these hospitals have found themselves scraping by due to the zero percent mark-up policy.Wang Zhiying, Vice Director of the People's Hospital of Anxiang County in the city of Changde, Hunan Province, said four grassroots hospitals in Changde tested the essential medicine system as pilot projects, but the zero percent mark-up policy took away 60 to 70 percent of the hospitals' revenue.Wang was quoted by "Health News," a newspaper run by China's Ministry of Health, as saying that, due to financial difficulties, the county government had not yet channeled the 8 million yuan (1.2 million U.S.dollars) in support funds into the hospitals' accounts, resulting in the resignations of many doctors.The essential medicine system covers 60 percent of government-funded grassroots hospitals and drug prices have fallen by an average of 30 percent, said Sun Zhigang, Director of the Health Reform Office under the State Council, or China's Cabinet.According to the health reform plan for 2011, the essential medicine system will cover all government-sponsored health institutions at the grassroots level by the end of the year and drugs will be sold there at a zero percent mark-up.Song Wenzhi said the key will be the commitment of local governments to health reform and their financial input. This way, essential medicines can benefit the public without bankrupting grassroots health institutions."That would be a great sum of money." said Song, citing his own studies. "There are roughly 5,000 government-funded hospitals in China. One third of them make profits, one third barely break even, and still one third rely heavily on government subsidies."To maintain the poorest hospitals, central and local level governments would need to invest 15 billion yuan (2.3 billion U.S. dollars) each year, according to Song's estimate.

UNITED NATIONS, Jan. 26 (Xinhua) -- China on Wednesday welcomed the smooth development of the south Sudan referendum, voicing its hope that the parties in south and north Sudan could reach a consensus at an early date on the outstanding issues through dialogue and consultations.Li Baodong, the Chinese permanent representative to the United Nations, made the statement in an interview with Xinhua after he spoke at the UN Security Council about the Chinese stance on the situation of Sudan.Earlier on Wednesday, the Security Council met to hear briefings from Atul Khare, UN assistant secretary-general for peacekeeping operations, and Ibrahim Gambari, the joint special representative of the African Union-United Nations Mission in Darfur (UNAMID), on the current situation in Sudan."China welcomes the smooth development of the south Sudan referendum, this is the result of the joint efforts of north and south Sudan and the international community," Li said."At present, priority should be given to the following work: First, continuous efforts should be made to fully maintain peace and stability in Sudan to enable the country to realize its long- term peace, stability and development," he said. "Second, efforts should be made to encourage the parties in south and north Sudan to continue their efforts for the full implementation of the Comprehensive Peace Agreement (CPA), particularly for a consensus at an early date on the outstanding issues."The referendum, with its week-long polling period ending on Jan. 15, will determine whether south Sudan remains a part of Sudan or becomes independent, in accordance with the 2005 CPA that ended a long-running north-south civil war.The referendum's preliminary results are expected to be announced by Feb. 2, and depending on whether appeals are launched in the courts, the final result will be declared on Feb. 7 or 14.

BEIJING, Jan. 27 (Xinhua) -- A senior Chinese official has called on the country's religious figures to make more contributions to economic and social development by innovating and improving social services.Jia Qinglin, a member of the Standing Committee of the Political Bureau of the Communist Party of China (CPC) Central Committee, made the remark at a meeting Thursday while offering lunar New Year's greetings to religious circles on behalf of the CPC Central Committee.Jia Qinglin (front, R), chairman of the National Committee of the Chinese People's Political Consultative Conference (CPPCC), and a member of the Standing Committee of the Political Bureau of the Communist Party of China (CPC) Central Committee, shakes hands with one of the leaders of the religious groups during an informal discussion sponsored by CPPCC in Beijing, capital of China, Jan. 27, 2011, to celebrate the upcoming Spring Festival.Jia said Chinese citizens' freedom in religious belief was fully protected, and the religious circles had provided excellent services for people from around the world during the Shanghai World Expo and Guangzhou Asian Games last year.The official asked the religious circles to pay more attention to helping grassroots religious groups and believers and improving their management.

BEIJING, Jan. 26 (Xinhua) -- China remained a major victim of trade protectionism during the past year, witnessing 64 trade disputes in this period, covering some 7 billion U.S. dollars in value, China's Vice Commerce Minister, Zhong Shan, said here Wednesday.The country faced trade disputes with both developed countries and developing ones, which came from not only traditional sectors but also high-tech industries, he told a national conference on trade promotion.For the short- and mid-term, China would work to maintain a stable growth in foreign trade and keep the growth rate higher than both the global level and China's economic growth, he said.China would also strive to achieve a more balanced trade structure by boosting imports and outbound investment, to strengthen the quality and efficiency of foreign trade, he added.China's foreign trade last year jumped 34.7 percent year on year to more than 2.97 trillion U.S. dollars, while its trade surplus fell 6.4 percent to 183.1 billion U.S. dollars.

来源：资阳报